Abstract Details

Title Quantifying Gait Parameters in Parkinson’s Disease and Essential Tremor via 3D Kinematics

Topic Movement Disorders

Presentation(s) P11 - Poster Session 11 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-011

Objective To compare gait parameters in a large cohort of Parkinson’s Disease (PD) and Essential Tremor (ET) patients using 3D kinematic analysis.

Background PD and ET are common movement disorders with gait abnormalities and associated morbidity, particularly in advanced disease. We aim to quantify gait parameters in these two conditions.

Design/Methods This retrospective study reviewed gait variables from a cohort of PD (n=245) and ET (n=123) patients who underwent 3D gait motion analysis (MA) between 2014 and 2022. Standard gait testing protocol included walking straight, with and without turns (≥5 cycles). Mean and standard deviation statistics for gait speed (m/s), cadence (steps/min), step length (cm), and step width (cm) were stratified by diagnosis, sex, and age. Differences in gait outcomes between PD and ET were assessed with linear models with terms for sex and age.

Results In 368 patients (67% PD; 33% ET), 34% were female and mean age was 65.7±10.5 years. After controlling for age and gender, linear models identified significant differences in gait speed (PD 85.9±31.5 cm/s vs. ET 92.6±25.3 cm/s, p=0.001), step length (PD 47.4±15.2 cm vs. ET 52.4±12.4 cm, p<<0.001), and step width (PD 11.8±3.4 cm vs. ET 12.9±4 cm, p=0.001) in PD compared to ET, but no difference in cadence (p=0.201). Female sex and increasing age were also associated with reduced gait speed and step length.

Conclusions

This is a large 3D gait MA cohort comparing PD and ET patients, demonstrating reduced gait speed and step length in PD and increased step width in ET, consistent with known pathology. Further comparisons with a larger sample size to age matched norms, longitudinally within and across disease states, are important to establish quantitative measures of gait natural history evolution in PD and ET. These data may provide improved clinical management and outcomes to potentially reduce falls and increase quality of life.

Authors/Disclosures
Keerthana Nalamada, MBBS (Emory University Brain Health Center) PRESENTER	Dr. Nalamada has received personal compensation in the range of $50,000-$99,999 for serving as a Movement Disorder Fellow with Parkinson's Foundation.
Johnathan L. McKay, PhD (Emory University)	The institution of Dr. McKay has received research support from NIH. The institution of Dr. McKay has received research support from the McCamish Foundation.
Sofia Hefner	Miss Hefner has nothing to disclose.
Douglas Bernhard	No disclosure on file
Richa Tripathi, MD (Emory University)	Dr. Tripathi has nothing to disclose.
Stewart A. Factor, DO, FAAN (Emory University School of Medicine)	Dr. Factor has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Factor has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Factor has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. The institution of Dr. Factor has received research support from Biohaven. The institution of Dr. Factor has received research support from Neurocrine. The institution of Dr. Factor has received research support from Supernus. The institution of Dr. Factor has received research support from Sun Pharmaceuticals Advanced Research Company. The institution of Dr. Factor has received research support from Aspen. The institution of Dr. Factor has received research support from RHO. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care.
Christine D. Esper, MD, FANA, FAAN (Emory Brain Health Center)	Dr. Esper has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parkinson's Study Group. Dr. Esper has received research support from Centers for Disease Control and Prevention. Dr. Esper has received research support from Michael J. Fox Foundation. Dr. Esper has received research support from McCamish Parkinson's Disease Innovation Program. Dr. Esper has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��